Physician profile
Mark E Aebi
NPI 1760461693
$2,112.23
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $71.26 · 2021: $378 · 2022: $709 · 2023: $555 · 2024: $41.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.03 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $233.42 | 2022-2023 | Ubrelvy, Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $165.95 | 2019-2022 | |
| Amgen INC. | $161.52 | 2019-2023 | Evenity, Prolia |
| Abbott Laboratories | $126.31 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $105.99 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $99.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $96.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.20 | 2021-2022 | |
| Glaxosmithkline, LLC. | $72.98 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $71.68 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $67.47 | 2019-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.27 | 2019-2023 | Jardiance |
| Pfizer INC. | $51.64 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47.94 | 2022-2023 | Mounjaro |
| Amarin Pharma, INC. | $44.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.89 | 2019-2022 | |
| Dexcom, INC. | $32.82 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.57 | 2019-2020 | |
| Boston Scientific Corporation | $21.00 | 2021 | |
| Corcept Therapeutics | $19.29 | 2024 | Korlym |
| Cardiovascular Systems INC. | $18.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.58 | 2019 | |
| Medtronic, INC. | $14.35 | 2023 | Linq II |
| Lucid Diagnostics INC. | $13.47 | 2022 | |
| Daiichi Sankyo INC. | $13.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.62 | 2022 | |
| Medtronic Vascular, INC. | $12.00 | 2019 | |
| Kci USA, INC. | $10.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Aebi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.